Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sacituzumab tirumotecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sacituzumab tirumotecan overview

sacituzumab tirumotecan (SKB-264) is under development for the treatment of ovarian epithelial cancer, gastric adenocarcinoma, triple negative breast cancer, endometrial carcinoma, HER2 negative breast cancer,  HER2-negative gastroesophageal junction adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, colorectal cancer, bile duct cancer, head and neck cancer squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, metastatic cervical cancer, metastatic castration-resistant prostate cancer, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma and Urothelial cancers. It is a third-generation antibody-drug conjugate that acts by targeting cells expressing (trophoblast antigen) TROP2. It is administered through intravenous route in the form of powder. The drug candidate is being developed based on the ADC conjugation technology.

It was under development for the treatment of pancreatic ductal adenocarcinoma, colorectal cancer and bladder cancer.

Merck overview

Merck is a biopharmaceutical company with focus on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for the treatment of cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes, among others. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is headquartered in Rahway, New Jersey, the US.

For a complete picture of Sacituzumab tirumotecan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.